Literature DB >> 30569502

Inspiratory muscle strength training improves lung function in patients with the hypermobile Ehlers-Danlos syndrome: A randomized controlled trial.

Gregory Reychler1,2,3, Giuseppe Liistro1,2, Gérald E Piérard4, Trinh Hermanns-Lê4, Daniel Manicourt5,6.   

Abstract

As exertional inspiratory dyspnea is a common disabling complaint in hypermobile Ehlers-Danlos syndrome (hEDS) often also known as joint hypermobility syndrome (JHS), we investigated inspiratory muscle (IM) strength in patients with hEDS, and we assessed the effects of IM training (IMT) on IM strength, lung function, and exercise capacity. A prospective evaluation of IM strength followed by a randomized controlled trial of IMT was performed in women with hEDS. Sniff nasal inspiratory pressure (SNIP) was used to routinely measure IM strength and IMT was carried out using a pressure threshold device. IM strength (main outcome), cardiopulmonary function, exercise capacity, and emotional distress of both the treated and control groups were evaluated at the start and at the end of the 6-week training period. IM strength was reduced (<80% of predicted) in 77% of patients (80/104). Lung function was normal, although 24% of patients had a higher forced expiratory vital capacity (FVC) than normal and 12% of patients had a higher total lung capacity (TLC) than normal. Both the IMT and control groups (n = 20) had similar baseline characteristics. Significant changes were noted only in the IMT group after IMT. At the end of the program, IMT improved SNIP (20%) (before: 41 ± 17 cm H2 O [28, 53] vs. after: 49 ± 18 cm H2 O [34;65]), six-minute walking distance (6MWD) (60 m) (455 ± 107 m [379,532] vs. 515 ± 127 m [408, 621]), and forced expiratory volume in one second (FEV1) (285 mL) (94 ± 14% pred [84,104] vs. 103 ± 11% pred [94, 112]). IM strength is significantly reduced in patients with hEDS. IMT improved IM strength, lung function, and exercise capacity. Our findings suggest that IMT should be added to usual care.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  connective tissue disease associated lung disease; exercise; lung physiology

Mesh:

Year:  2018        PMID: 30569502     DOI: 10.1002/ajmg.a.61016

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

1.  Evidence of ventilatory constraints during exercise in hypermobile Ehlers-Danlos syndrome.

Authors:  Adrien Hakimi; Cyrille Bergoin; Patrick Mucci
Journal:  Eur J Appl Physiol       Date:  2022-08-08       Impact factor: 3.346

2.  The effectiveness of conservative interventions for the management of syndromic hypermobility: a systematic literature review.

Authors:  Shea Palmer; Indi Davey; Laura Oliver; Amara Preece; Laura Sowerby; Sophie House
Journal:  Clin Rheumatol       Date:  2020-07-17       Impact factor: 2.980

Review 3.  Exercise and Rehabilitation in People With Ehlers-Danlos Syndrome: A Systematic Review.

Authors:  Stephanie Buryk-Iggers; Nimish Mittal; Daniel Santa Mina; Scott C Adams; Marina Englesakis; Maxim Rachinsky; Laura Lopez-Hernandez; Laura Hussey; Laura McGillis; Lianne McLean; Camille Laflamme; Dmitry Rozenberg; Hance Clarke
Journal:  Arch Rehabil Res Clin Transl       Date:  2022-03-04

Review 4.  Rationale and Feasibility of Resistance Training in hEDS/HSD: A Narrative Review.

Authors:  Hannah A Zabriskie
Journal:  J Funct Morphol Kinesiol       Date:  2022-08-20

Review 5.  Multidisciplinary Approach to Treating Chronic Pain in Patients with Ehlers-Danlos Syndrome: Critically Appraised Topic.

Authors:  Kiley C Whalen; Wilson Crone
Journal:  J Pain Res       Date:  2022-09-13       Impact factor: 2.832

Review 6.  A review of respiratory manifestations and their management in Ehlers-Danlos syndromes and hypermobility spectrum disorders.

Authors:  Karan Chohan; Nimish Mittal; Laura McGillis; Laura Lopez-Hernandez; Encarna Camacho; Maxim Rachinsky; Daniel Santa Mina; W Darlene Reid; Clodagh Mai Ryan; Kateri Agnes Champagne; Ani Orchanian-Cheff; Hance Clarke; Dmitry Rozenberg
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 2.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.